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A commentary on
Effect of acetazolamide on visual func-
tion in patients with idiopathic intracra-
nial hypertension and mild visual loss:
the idiopathic intracranial hypertension
treatment trial
by Wall M, McDermott MP, Kieburtz KD,
Corbett JJ, Feldon SE, Friedman DI, et al.
(2014). JAMA 311:1641–51. doi:10.1001/
jama.2014.3312
We wish to comment on the correspon-
dence regarding the question of efficacy
and mechanism of action of acetazolamide
in the treatment of idiopathic intracranial
hypertension (IIH), published in JAMA
September 10, 2014 (1). Whereas Sinclair
et al. (2) minimize the benefits and favor
a theory of weight loss as the reason for
a small improvement in symptoms and
reduced papilledema, Wall et al. (3) hold
that acetazolamide has a direct effect on
papilledema and intracranial pressure, and
significantly improves visual field function
in a patient with IIH. The distribution of
carbonic anhydrase and acetazolamide in
the brain and how that relates to the mech-
anism of action of acetazolamide in IIH are
not addressed.
In the 1950s, a similar discussion con-
cerned the mechanism of acetazolamide
in the treatment of epileptic seizures. Ini-
tially, it was thought that the effect was
indirect via the kidneys and was related
to an induced metabolic acidosis. Subse-
quently, acetazolamide was shown to pre-
vent seizures in nephrectomized animals;
the anticonvulsant effect was independent
of the effect on the kidneys and was caused
by a direct inhibition of carbonic anhydrase
in the brain (4).
In patients with IIH treated with aceta-
zolamide, the inhibition of the enzyme in
the choroid plexus results in a reduction
of CSF production and flow. The acid–
base status of the patient may also alter
the distribution of acetazolamide in the
CSF and brain, but its effect on the CSF
flow is secondary to that mediated by the
choroid plexus. Based on the pharmacol-
ogy and distribution of acetazolamide and
carbonic anhydrase in the brain, the theory
that emphasizes the effect of acetazolamide
on CSF production in IIH is most likely
primary and direct, and weight loss, when
recognized as a factor, is secondary and
indirect, and frequently the result of toxic
doses in excess of the amount needed for
complete enzyme inhibition.
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